The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.
 
Umang Swami
Consulting or Advisory Role - Seagen
Research Funding - Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Agnes Hong
Employment - Astellas Pharma
Honoraria - Abbvie; Merck; Veru
 
Nader N. El-Chaar
Employment - Astellas Pharma
 
David Nimke
Employment - Astellas Pharma
 
Krishnan Ramaswamy
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Brandon Diessner
Employment - OptumHealth
Research Funding - Astellas Pharma; AstraZeneca; Daiichi Sankyo; Optum/UnitedHealth Group; Pfizer
 
Rickard Sandin
Employment - Pfizer
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech; Janssen; Lilly; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pharmacyclics; Seagen
Research Funding - Active Biotech; Amgen; AstraZeneca; Bavarian Nordic; Bayer; BN ImmunoTherapeutics; Bristol-Myers Squibb; Calithera Biosciences; Celldex; Eisai; Exelixis; Genentech; GlaxoSmithKline; Immunomedics; Janssen; Merck; Newlink Genetics; Novartis; Pfizer; Prometheus; Rexahn Pharmaceuticals; Sanofi; Takeda; TRACON Pharma